Hong Kong Pharmaceuticals Stock News

Frost & Sullivan’s 2026 AI Infrastructure Orchestration Platform White Paper recently named Phancy Group’s Rise vGPU a Tier 1 Leading Platform and ranked its ModelHub offering highest among model management platforms, citing strengths in handling heterogeneous AI infrastructure and improving GPU utilization. This independent recognition underscores Phancy Group’s role in pushing China’s AI ecosystem toward a “compute orchestration” era rather than sheer compute accumulation, highlighting the...

XtalPi Holdings (SEHK:2228) has drawn fresh investor attention after announcing a new R&D alliance with a global biopharmaceutical partner to co-develop an oral small molecule therapy targeting a complex GPCR receptor. See our latest analysis for XtalPi Holdings. XtalPi Holdings' recent R&D alliance arrives after a weak run in the share price, with the 30 day share price return down 16.33% and the year to date share price return down 33.83%, even as the 1 year total shareholder return is...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Fresh U.S. tariff proposals of up to 12.5% on imports from 60 economies are reshaping the risk profile for globally exposed stocks, especially those tied to complex cross border supply chains. With partial exemptions for electronics and AI related products, some areas may find a softer landing while others face higher costs and potential pressure on margins. This article focuses on three stocks that appear negatively exposed to the latest trade policy headlines and explains how these tariff...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

It looks like TCL Electronics Holdings Limited ( HKG:1070 ) is about to go ex-dividend in the next 4 days. The...

Get Nice Holdings (SEHK:64) has reported fresh numbers for FY 2026, with first half revenue of HK$161.1 million and basic EPS of HK$0.08, alongside trailing twelve month revenue of HK$222.2 million and EPS of HK$0.09, against a current share price of HK$3.31. Over recent periods the company has seen revenue move from HK$214.6 million in the first half of FY 2025 to HK$220.7 million in the second half, while EPS shifted from HK$0.07 to HK$0.02. This sets the backdrop for the latest figures and...

BYD (SEHK:1211) has received over 150,000 pre orders for its new flagship Great Tang electric SUV. The company is preparing to launch the Great Tang in Europe alongside increased investment in European manufacturing and R&D. These moves raise questions about BYD's ability to scale production and support overseas growth while meeting international demand. BYD enters this phase with its share price at HK$80.85, after the stock declined 6.6% over the past week and 10.4% over the past month...

RemeGen (SEHK:9995) is back in focus after China’s National Medical Products Administration approved new indications for its autoimmune drug Telitacicept in Sjögren’s disease and conditionally in IgA nephropathy, expanding its treated patient pools. See our latest analysis for RemeGen. At a latest share price of HK$68.5, RemeGen’s 1 day share price return of 1.63% follows a 30 day share price decline of 19.32%. Its 1 year total shareholder return of 37.27% and 3 year total shareholder return...

A unit of Kingboard Holdings recently moved to raise about US$1.50 billion through a block trade of shares in Kingboard Laminates, adjusting its financing mix and ownership structure in the process. This fundraising comes as Kingboard Laminates benefits from very strong AI server demand for high-grade laminates and copper foil, where tight supply has turned into concrete order pressure. We will now examine how this large capital raise, set against constrained AI server material supply,...

CARsgen Therapeutics Holdings recently presented early clinical data at the 2026 European Hematology Association Congress showing its allogeneic CAR T-cell candidates CT0596 and CT1190B produced high response rates with manageable safety in heavily pretreated blood cancer patients. An interesting aspect for investors is that both products are off-the-shelf allogeneic CAR T therapies, with responses seen even in patients previously treated with CAR T or bispecific antibodies. We will now...

Akeso (SEHK:9926) is back in focus after presenting Phase II data for its anti CD47 antibody ligufalimab in acute myeloid leukemia at the 2026 European Hematology Association Congress, highlighting survival and response outcomes versus standard therapy. See our latest analysis for Akeso. Akeso's HK$87.55 share price has seen a 4.35% 1 day gain but is still down 22.38% over 30 days and 24.26% over 90 days. The 3 year total shareholder return of 152.67% contrasts with a 4.89% decline over the...

In recent weeks, global markets have shown mixed performances, with the U.S. indices like the Nasdaq Composite and Russell 2000 posting gains amid geopolitical developments and steady interest rates from the Federal Reserve. As investors navigate this environment of cautious optimism and potential rate hikes, small-cap stocks present intriguing opportunities due to their growth potential and often overlooked value. In this context, identifying stocks with strong fundamentals and insider...

Hong Kong is preparing to launch trading of Chinese treasury futures in offshore yuan on August 3, 2026, opening another channel for investors who care about currency risk, fixed income exposure, and deeper access to China’s markets. As yuan denominated products expand and hedging tools improve, some Hong Kong financial stocks could see stronger trading flows or more client demand, while others may see little direct benefit. This article walks through three Hong Kong Financials and Exchange...

As the Asian markets navigate a complex landscape shaped by global economic shifts and regional developments, investors are increasingly looking for opportunities that can offer growth potential. Penny stocks, often representing smaller or emerging companies, continue to attract attention due to their affordability and potential for significant returns. Despite being an older term, penny stocks remain relevant as they can provide value when backed by strong financial health and solid...

It looks like Boyaa Interactive International Limited ( HKG:434 ) is about to go ex-dividend in the next four days...

By selling CN¥13m worth of Fullshare Holdings Limited ( HKG:607 ) stock at an average sell price of CN¥0.34 over the...

It looks like Nexteer Automotive Group Limited ( HKG:1316 ) is about to go ex-dividend in the next 4 days. The...

The recent price decline of 16% in China High Speed Transmission Equipment Group Co., Ltd.'s ( HKG:658 ) stock may have...

Some IPE Group Limited ( HKG:929 ) shareholders may be a little concerned to see that insider Siu On Chui recently sold...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see COSCO...

Potential Texwinca Holdings Limited ( HKG:321 ) shareholders may wish to note that the Executive Chairman of the Board...

In the current landscape, Asian markets are navigating a complex mix of resilient industrial activity and persistent domestic challenges, as seen in China, while Japan's stock markets continue to reach new heights driven by technology and semiconductor sectors. Against this backdrop, identifying growth companies with significant insider ownership can offer insights into potential investment opportunities, as these companies often demonstrate strong internal confidence and alignment with...